by Alison Birtle | 5 June 2024 | Urogenital
Enfortumab vedotin (EV) plus pembrolizumab has recently been established as the new first-line treatment standard in advanced urothelial carcinoma. Clear guidance on how to manage the typical side effects of this regimen is necessary to allow for the successful use of...
